ATG + cyclophosphamide

ATG + cyclophosphamide is a combination regimen consisting of antithymocyte globulin (ATG), a polyclonal antibody preparation targeting human T cells, and cyclophosphamide, an alkylating agent with immunosuppressive and cytotoxic properties. This combination is primarily used as part of conditioning or graft-versus-host disease (GVHD) prophylaxis regimens in allogeneic hematopoietic stem cell transplantation (HSCT), especially in settings such as haploidentical or unrelated donor transplants for hematological malignancies and aplastic anemia. - **Mechanism of Action:** - ATG depletes T lymphocytes by binding to multiple surface antigens on human T cells, leading to their destruction via complement-mediated lysis and opsonization. - Cyclophosphamide acts as an alkylating agent that crosslinks DNA strands, resulting in cell death; when used post-transplant (PTCy), it selectively eliminates proliferating alloreactive T cells responsible for GVHD while sparing regulatory immune populations. The combination aims to reduce both acute and chronic GVHD rates without increasing relapse or infection risk compared to single-agent regimens[1][3][5]. It has been shown effective in improving survival outcomes in patients undergoing HSCT for conditions like hematological malignancies and severe aplastic anemia[2].

Other names

antithymocyte globulin + cyclophosphamideATG/PTCyATG/PT-Cy